KEYNOTE-522 |
III |
pCR and EFS in ITT |
Untreated stage II–III TNBC patients (n=1,174) |
Neoadjuvant TCb → AC ± pembro, followed by pembro (or placebo) for 1 year after surgery |
64.8% vs 51.2%; p<0.001 |
-
3-year EFS: 84.5% vs 76.8% (HR: 0.63 [95% CI: 0.48–0.82]; p=0.0003)
-
3-year DDFS: 87% vs 80.7% (HR: 0.61 [95% CI: 0.46–0.82])
-
3-year OS: 89.7% vs 86.9% (HR: 0.72 [95% CI: 0.51–1.02]; p=0.032)
|
[@111734] |
IMpassion031 |
III |
pCR in ITT and in PD-L1+ patients |
Untreated stage II–III TNBC patients (n=333) |
Neoadjuvant nabT → AC ± atezo, followed by atezo (or placebo) for 1 year after surgery (capecitabine also allowed) |
58% vs 41%; p=0.0044 |
-
EFS HR: 0.76 (95% CI: 0.40–1.40)
-
DFS HR: 0.74 (95% CI: 0.32–1.70)
-
OS HR: 0.69 (95% CI: 0.25–1.87)
|
[@111770] |
NeoTRIPaPDL1 |
III |
EFS |
Untreated stage II–III TNBC patients (n=280) |
Neoadjuvant nabTCb ± atezo, followed by adjuvant anthracyclines after surgery |
43.5% vs 40.8% (OR: 1.11 [95% CI: 0.69–1.79]; p=0.66) |
Pending |
[@111771] |
GeparNuevo |
II |
pCR in ITT |
Untreated stage I–III TNBC patients (n=174) |
Neoadjuvant nabT → AC ± durva, followed by physician’s choice of adjuvant treatment after surgery |
53.4% vs 44.2% (OR: 1.45 [95% CI: 0.80–2.63]; p=0.287) |
-
3-year iDFS: 84.9% vs 76.9% (HR: 0.54 [95% CI: 0.27–1.09]; p=0.0559)
-
3-year DDFS: 91.4% vs 79.5% (HR: 0.37 [95% CI: 0.15–0.87]; p=0.0148)
-
3-year OS: 95.1% vs 83.1% (HR: 0.26 [95% CI: 0.09–0.79]; p=0.0076)
|
[@111772] |
I-SPY2 |
II |
pCR in ITT |
Untreated stage II–III TNBC and HR+/HER2- BC patients (n=107) |
Neoadjuvant T → AC ± pembro, followed by physician’s choice of adjuvant treatment after surgery |
60% vs 22% (TNBC patients) |
- EFS HR: 0.60 (TNBC patients)
|
[@111773] |